CompletedNot Applicable

Pooled Analysis of Patients With Early-stage Breast Cancer Treated With Adjuvant Dose-dense Sequential Chemotherapy: a Hellenic Cooperative Oncology Group (HeCOG) Study.

Greece5,358 participantsStarted 1996-12-15

Plain-language summary

The goal of this observational study is to assess survival outcomes and treatment-related toxicity in patients with early-stage breast cancer receiving adjuvant therapies, using high-quality individual patient data pooled from seven clinical studies conducted by the Hellenic Cooperative Oncology Group (HeCOG), including 3 phase III trials and 4 observational studies. This study aims to assess long-term disease-free survival (DFS) and overall survival (OS), as well as the toxicity patterns associated with dose-dense sequential chemotherapy in intermediate or high-rsk patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with early-stage, surgically resected breast cancer (high or intermediate risk), randomized to receive adjuvant or neoadjuvant dose-dense sequential chemotherapy. Exclusion Criteria: * Patients with metastatic or locally advanced breast cancer at initial diagnosis. Patients who did not receive dose-dense sequential chemotherapy.

What they're measuring

Disease-Free Survival

Timeframe: From date of diagnosis or surgery to first documented recurrence or death.

Trial details

NCT IDNCT07521397

SponsorHellenic Cooperative Oncology Group

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-07-15

View on ClinicalTrials.gov More Breast Cancer trials